ONE CAVENDISH PLACE, LONDON, X0
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
Announce Option and License Agreement for Alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Amended material disclosure
Reports First Quarter 2026 Financial Results and Provides Corporate Highlights
Annual Report to Security Holders
Director Departure - Dr. Annalisa Jenkins Not Standing for Re-Election
Reports Full Year 2025 Financial Results and Provides Corporate Highlights
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership